| 发明名称 | Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart | ||
| 摘要 | The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof. | ||
| 申请公布号 | US9289470(B2) | 申请公布日期 | 2016.03.22 |
| 申请号 | US201414306992 | 申请日期 | 2014.06.17 |
| 申请人 | PHILOGEN S.P.A. | 发明人 | Neri Dario;Menssen Hans;Menrad Andreas;Schliemann Christoph |
| 分类号 | C07K16/30;C07K14/55;C07K16/46;C07K16/28;A61K39/395;A61P35/00;A61P37/06;A61K38/20;A61K47/48;A61K39/44;A61K45/06;A61K51/10;C07K16/18;A61K39/00 | 主分类号 | C07K16/30 |
| 代理机构 | Millen, White, Zelano, Branigan, P.C. | 代理人 | Millen, White, Zelano, Branigan, P.C. |
| 主权项 | 1. A combination comprising at least (i) a fusion protein comprising two parts, wherein the first part is an antibody or a fragment thereof which specifically recognizes an extra domain B (EDb) of fibronectin, wherein said antibody is L19, and the second part is an Interleukin-2 polypeptide comprising the amino acid sequence of SEQ ID NO: 4; and (ii) an antibody or an antigen-binding fragment thereof or a fusion protein comprising said antibody or said antigen-binding fragment thereof that specifically binds to CD20, wherein the anti-CD20 antibody is selected from the group consisting of rituximab, PRO131921, Veltuzumab, Ofatumumab, and AME-133. | ||
| 地址 | Sienna IT | ||